Year-End Report 2018

The Board of Directors and the CEO reports the following for the fiscal year 2018. Unless otherwise stated, all amounts are reported in integers SEK (SEK). Data in parentheses refer to the previous year.

Summary of the year-end report

TWELVE MONTHS (January – December 2018) 

  • The company’s sales amounted to 41 (0) KSEK. 
  • Other operating income amounted to 17 (153) KSEK. 
  • Capitalised development expenses amounted to 427 (694) KSEK. 
  • Costs amounted to 9,795 (8,995) KSEK. 
  • Result before and after tax amounted to -9,311 (-8,148) KSEK. 
  • Result per share amounted to -0.94 (-0.94) SEK. 
  • Cash and cash equivalents at the end of the period amounted to 12,889 KSEK. 
  • The board and the CEO propose that no dividend be paid for the financial year 2018-01-01 – 2018-12-31. 

FOURTH QUARTER (October – December 2018) 

  • The company’s sales amounted to 41 (0) KSEK. 
  • Other operating income amounted to 0 (0) KSEK. 
  • Capitalised development expenses amounted to 0 (172) KSEK. 
  • Costs amounted to 2,747 (3,110) KSEK. 
  • Result before and after tax amounted to 2,706 (2,938) KSEK. 
  • Result per share amounted to 0,26 (-0,33) KSEK. 

Results in brief 

KSEK  2018 Oct – Dec  2017 Oct – Dec  2018 Jan – Dec  2017 Jan – Dec 
Operating income  41  172  485  847 
Operating costs  -2,747  -3,110  -9,795  -8,995 
Operating result  -2,706  -2,938  -9,310  -8,148 
Result for the period  -2,706  -2,938  -9,311  -8,148 

CEO Karin Bryder summarises the quarter 

In the beginning of October, we were able to finally launch the first Arcamea product Efemia Bladder Support via arcamea.se after a strong finish of the development phase in 2018. Thanks to our strategy to initiate discussions early with potential distribution partners, we were able to announce  that  an  evaluation  of the  product  was initiated in Germany during the quarter. The first agreement, with Sweden’s largest pharmacy chain Apoteket 

AB, was then presented after the end of the period. We were also able to initiate a post-launch study during the quarter with Aller media, and the company received notification on an additional patent approval in the USA.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

This information is information that Invent Medic Sweden AB (publ) is obliged to make public.The information was submitted for publication, through the agency of the contact person set out above, on February 22, 2019.

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.

Subscribe

Documents & Links